Ellebasy Medicale Trading is a Filipino-owned pharmaceutical company that imports and distributes a wide array of generic medicines. Its founder, Mr. Jake M. Aguado, has been with several pharmaceutical companies – both multi-national and local – when he finally decided that he wanted to establish his own generic drugs trading company.
Read More →A sedative hypnotic agent that can be used as Initiation and Maintenance of monitored Anesthesia Care (MAC) sedation, Combined sedation and regional anesthesia, Intensive Care Unit (ICU) sedation of intubated mechanically intubated patients, Induction General anesthesia, Maintenance of General Anesthesia.
For the management of motion sickness and other forms of nausea and vomiting, also a premedicant in anaesthesia, and to produce cycloplegia and mydriasis and in condition associated with visceral spasm.
Parenteral nutrition supplement in condition e.g acute and chronic renal insufficiency, hemofiltration & hemodialysis, and to improve nutrition statement before and after surgery.
Used, often with other antineoplastic in the treatment of Hodgkin’s Disease, Non-Hodgkin’s Disease lymphomas, acute leukemia’s, bone and soft tissue sarcomas, nuero blastoma, Wilm’s tumor and Malignant neoplasm of the bladder, breast, lungs , ovary, and stomach. It has also been used in other tumors.
For supply of amino acid in hypoproteinemia, malnutrition, pre-and post-operative support.
This medication is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. Zoledronic acid is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer (such as breast, lung) that have spread to the bones.
Used, often with other antineoplastic in the treatment of Hodgkin’s Disease, Non-Hodgkin’s Disease lymphomas, acute leukemia’s, bone and soft tissue sarcomas, nuero blastoma, Wilm’s tumor and Malignant neoplasm of the bladder, breast, lungs , ovary, and stomach. It has also been used in other tumors.
Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test